Haemonetics (HAE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

HAE Haemonetics

Watchlist

85.550
+0.120+0.14%

Close Nov 22 16:00 ET

85.550
0.0000.00%

Post 16:08 ET

4.30BMarket Cap35.50P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Here's Why You Should Add OMCL Stock to Your Portfolio Now
Zacks Nov 18 07:00 ET
Needham Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $112
Moomoo NewsNov 15 06:31 ET · Ratings
Strategic Investment and Growth Potential Drive Buy Rating for Haemonetics
TipRanksNov 15 06:16 ET · Ratings
Haemonetics Management to Meet Virtually With BTIG
TipRanksNov 14 16:05 ET
Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock
Zacks Nov 14 09:00 ET
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
Zacks Nov 14 07:30 ET

Comments

Tonyco

7 hours ago

Columns Shortages and affected stocks

Saline shortage:
$Baxter International Inc (BAX.US)$
$Fresenius Medical Care (FMS.US)$
$Rockwell Medical (RMTI.US)$ (adj ind.)
$Compass Minerals (CMP.US)$
(chemical for saline)
ADD meds:
$Teva Pharmaceutical Industries (TEVA.US)$
$Pfizer (PFE.US)$
$Cingulate (CING.US)$
EVH (endoscopic vessel harvesting) device shortage:
$TransMedics (TMDX.US)$
$Artivion (AORT.US)$
$Lantheus (LNTH.US)$
$Haemonetics (HAE.US)$
BGM (Blood glucose monitor) device shortage:
$DexCom (DXCM.US)$ $
$Abbott Laboratories (ABT.US)$
...

Moomoo AI

Mar 8 05:32

Despite a recent dip, Haemonetics' robust financials hint at potential long-term stock value growth. High ROE and profit reinvestment suggest promising earnings growth, with analysts predicting continued expansion.

Haemonetics Corporation (NYSE:HAE) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Moomoo AI

Jan 29 05:09

Despite the falling share price, the consistent growth in revenue and EPS could present an investment opportunity if the stock has fallen unfairly. Market expectations may have been unreasonable in the past.

The Three-year Underlying Earnings Growth at Haemonetics (NYSE:HAE) Is Promising, but the Shareholders Are Still in the Red Over That Time

Moomoo AI

Jan 2 07:33

Shareholders appear to hang onto Haemonetics, expecting it to keep beating market trends, due to its projected solid growth. Despite a high P/E, the predicted limited risk of an earnings drop keeps the share price stable.

Getting In Cheap On Haemonetics Corporation (NYSE:HAE) Might Be Difficult

Moomoo Breakfast US

Aug 30, 2022 07:34

Columns Today's Pre-Market Stock Movers: BBY, BIDU, LCID, FSLR and More

Gapping up
In reaction to earnings/guidance:
• $Gambling.com (GAMB.US)$ +5.5%, $Baidu (BIDU.US)$ +3.6%, $Best Buy (BBY.US)$ +2.4%, $Heico (HEI.US)$ +1.4%, $Big Lots (BIG.US)$ +0.6%
Other news:
• $FREYR Battery (FREY.US)$ +11.4% (announces the execution of 38 GWh Li-Ion Battery binding cell sales agreement; enters into module & pack JV for energy storage solutions with Nidec)
• $Avid Technology (AVID.US)$ +9.6% (to join S&P SmallCap 600)
• $RVL Pharmaceuticals (RVLP.US)$ +2.3% (Re...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

HAE Haemonetics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target